Literature DB >> 25072861

[Hyperammonemic encephalopathy in multiple myeloma].

A Oestmann1, D Aujesky1.   

Abstract

HISTORY AND CLINICAL
FINDINGS: A 54-year old man had suffered from advanced multiple myeloma for two years. After initially good response the myeloma was refractrory to treatment with dexamethasone, cyclophosphamide, bortezomibe, zoledronate and additionally doxorubicine. The patient then complained of dyspnea without clinical signs of cardiopulmonary disease. INVESTIGATIONS: Arterial blood gas analysis showed hyperventilation with respiratory alkalosis and normal alveolo-arterial gradient as the reason for the dyspnea. With a normal MRI of the brain and lumbal puncture, a neurological disease could be excluded. Serum calcium, creatinine and serum viscosity were normal. Eventually, serum ammonia levels were found to be substantially elevated (144 µmol/l) and hyperammonemic encephalopathy was diagnosed. TREATMENT AND COURSE: Therapy with bortezomib and high dose dexamethason was repeated, and the patient also received bendamustin. Despite this treatment, he lost consciousness and died after two weeks because of aspiration pneumonia.
CONCLUSION: The existence of respiratory alkalosis and multiple myeloma should prompt a search for hyperammonemia. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25072861     DOI: 10.1055/s-0034-1370132

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

1.  Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm.

Authors:  Claudia I Chapuy; Inderneel Sahai; Rohit Sharma; Andrew X Zhu; Olga N Kozyreva
Journal:  Oncologist       Date:  2016-03-14

2.  Multiple Myeloma-Induced Hyperammonemic Encephalopathy.

Authors:  Ghulam Murtaza; Hannah Lu; Anadil Faqah; Nicholas Konowitz; Aneesh Kuruvilla; Sujeen Adhikari
Journal:  J Hematol (Brossard)       Date:  2017-03-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.